000			01698 a2200517 4500
005			20250512023047.0
264		0	_c19860512
008			198605s 0 0 eng d
022			_a0140-6736
024	7		_a10.1016/s0140-6736(86)90937-2 _2doi
040			_aNLM _beng _cNLM
100	1		_aScully, B E
245	0	0	_aOral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa. _h[electronic resource]
260			_bLancet (London, England) _cApr 1986
300			_a819-22 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAdministration, Oral
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAnti-Bacterial Agents _xtherapeutic use
650	0	4	_aAnti-Infective Agents, Urinary _xtherapeutic use
650	0	4	_aChild
650	0	4	_aCiprofloxacin
650	0	4	_aConnective Tissue Diseases _xdrug therapy
650	0	4	_aCystic Fibrosis _xcomplications
650	0	4	_aDrug Evaluation
650	0	4	_aDrug Resistance, Microbial
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aOsteomyelitis _xdrug therapy
650	0	4	_aPneumonia _xdrug therapy
650	0	4	_aPseudomonas Infections _xdrug therapy
650	0	4	_aPseudomonas aeruginosa _xdrug effects
650	0	4	_aQuinolines _xadministration & dosage
650	0	4	_aTime Factors
650	0	4	_aWound Infection _xdrug therapy
700	1		_aNeu, H C
700	1		_aParry, M F
700	1		_aMandell, W
773	0		_tLancet (London, England) _gvol. 1 _gno. 8485 _gp. 819-22
856	4	0	_uhttps://doi.org/10.1016/s0140-6736(86)90937-2 _zAvailable from publisher's website
999			_c2876159 _d2876159